The TSX Venture Exchange has accepted for filing the share sale agreement (SSA) dated June 25, 2018, between the company and MMJ PhytoTech Ltd., an Australian company, to purchase 100 per cent of MMJ's wholly owned Israeli-based subsidiary, PhytoTech Therapeutics Ltd. (PTL). Consideration for PTL included: (i) a cash payment of $1-million; and (ii) the issuance of $7-million in shares of the company, which equated to 8,326,694 common shares.

The transaction was a non-arm's-length transaction as MMJ is a control entity of the company as defined under TSX Venture Exchange policy. There were no finders' fees on the transaction.

For further details of the transaction, refer to the company's news releases dated June 25, 2018, and Nov. 20, 2018.